Antiplatelet drug therapy: Role of pharmacodynamic and genetic testing

Future Cardiology

Volumn 7, Issue 3, 2011, Pages 381-402

  Tello Montoliu, Antonio ^a,b   Ueno, Masafumi ^a   Angiolillo, Dominick J ^a  

^a UNIVERSITY OF FLORIDA COLLEGE OF MEDICINE   (United States)

^b HOSPITAL UNIVERSITARIO VIRGEN DE LA ARRIXACA   (Spain)

Author keywords

antiplatelet therapy; aspirin; clopidogrel; genetic testing; platelet function testing

Indexed keywords

2' DEOXY 6 N METHYLADENOSINE 3',5' BISPHOSPHATE; 4 (2 IODO 6 METHYLAMINO 9H PURIN 9 YL) 2 PHOSPHONOOXYBICYCLO[3.1.0]HEXANE 1 METHANOL; ABCIXIMAB; ACETYLSALICYLIC ACID; ACETYLSALICYLIC ACID 3 (NITROXYMETHYL)PHENYL ESTER; ANTITHROMBOCYTIC AGENT; ATOPAXAR; CANGRELOR; CILOSTAZOL; CLOPIDOGREL; ELINOGREL; EPTIFIBATIDE; FIBRINOGEN RECEPTOR ANTAGONIST; MRS 2279; N [2 [4 (5H DIBENZO[A,D]CYCLOHEPTEN 5 YLIDENE)PIPERIDINO]ETHYL] 1 FORMYLISONIPECOTAMIDE; NAFTIDROFURYL; PICOTAMIDE; PRASUGREL; PURINERGIC P2Y12 RECEPTOR INHIBITOR; PURINERGIC RECEPTOR BLOCKING AGENT; R 1012444; RAMATROBAN; RIDOGREL; SARPOGRELATE; TERUTROBAN; TICAGRELOR; TICLOPIDINE; TIROFIBAN; UNCLASSIFIED DRUG; UNINDEXED DRUG; VORAPAXAR;

ACUTE CORONARY SYNDROME; ADVERSE OUTCOME; ANTICOAGULANT THERAPY; BLEEDING; BLOOD CLOTTING PARAMETERS; DRUG MEGADOSE; GENETIC SCREENING; HIGH RISK PATIENT; HUMAN; ISCHEMIA; LOADING DRUG DOSE; LOW DRUG DOSE; OPTIMAL DRUG DOSE; PERCUTANEOUS CORONARY INTERVENTION; PHARMACOGENETICS; PRIORITY JOURNAL; RECURRENT DISEASE; REVIEW; RISK ASSESSMENT; THROMBOSIS; TREATMENT RESPONSE;

ANGIOPLASTY, BALLOON, CORONARY; ASPIRIN; CORONARY ARTERY DISEASE; DRUG THERAPY, COMBINATION; HUMANS; PHARMACOGENETICS; PLATELET AGGREGATION INHIBITORS; PLATELET FUNCTION TESTS; TICLOPIDINE;

EID: 79958088303     PISSN: 14796678     EISSN: 17448298     Source Type: Journal    
DOI: 10.2217/fca.11.14     Document Type: Review

References (161)

1. Anderson JL, Adams CD, Antman EM, et al. ACC/AHA 2007 guidelines for the management of patients with unstable angina/non ST-elevation myocardial infarction: a report of the American College of Cardiology/American Heart Association Task Force on Practice Guidelines (Writing Committee to Revise the 2002 Guidelines for the Management of Patients With Unstable Angina/Non ST-Elevation Myocardial Infarction): developed in collaboration with the American College of Emergency Physicians, the Society for Cardiovascular Angiography and Interventions, and the Society of Thoracic Surgeons: endorsed by the American Association of Cardiovascular and Pulmonary Rehabilitation and the Society for Academic Emergency Medicine. Circulation 116 (17), e148-e304 (2007).
2. Angiolillo DJ: Variability in responsiveness to oral antiplatelet therapy. Am. J. Cardiol. 103(Suppl. 3), 27A-34A (2009).
3. Ferreiro JL, Sibbing D, Angiolillo DJ: Platelet function testing and risk of bleeding complications. Thromb. Haemost. 103(6), 1128-1135 (2010).
4. Born GV: Aggregation of blood platelets by adenosine diphosphate and its reversal. Nature 194, 927-929 (1962).
5. OBrien JR: Platelet aggregation: part II, some results from a new method of study. J. Clin. Pathol. 15(5), 452-455 (1962).
6. Favaloro EJ, Lippi G, Franchini M: Contemporary platelet function testing. Clin. Chem. Lab. Med. 48(5), 579-598 (2010).
7. Michelson AD: Platelet function testing in cardiovascular diseases. Circulation 110(19), e489-e493 (2004).
8. Williams CD, Cherala G, Serebruany V: Application of platelet function testing to bedsite. Thromb. Haemost. 103 (1), 29-33 (2010).
9. Marín F, González-Conejero R, Capranzano P, Bass TA, Roldán V, Angiolillo DJ: Pharmacogenetics in cardiovascular antithrombotic therapy. J. Am. Coll. Cardiol. 54(12), 1041-1057 (2009).
10. Gurbel PA, Tantry US, Shuldiner AR, Kereiakes DJ: Genotyping: one piece of the puzzle to personalize antiplatelet therapy. J. Am. Coll. Cardiol. 56(2), 112-116 (2010).
11. Bonello L, Tantry US, Marcucci R, et al. Working group on high on-treatment platelet reactivity. Consensus and future directions on the definition of high on-treatment platelet reactivity to adenosine diphosphate. J. Am. Coll. Cardiol. 56(12), 919-933 (2010).
12. Tantry US, Mahla E, Gurbel PA: Aspirin resistance. Prog. Cardiovasc. Dis. 52(2), 141-152 (2009).
13. Cattaneo M: Resistance to antiplatelet drugs: molecular mechanism and laboratory detection. J. Thromb. Haemost. 5(Suppl. 1), 230-237 (2007). (Pubitemid 46958838)
14. FitzGerald GA, Oates JA, Hawiger J, et al. Endogenous biosynthesis of prostacyclin and thromboxane and plateletfunction during chronic administration of aspirin in man. J. Clin. Invest. 71(3), 678-688 (1983).
15. Cipollone F, Rocca B, Patrono C: Cyclooxygenase-2 expression and inhibition in atherothrombosis. Arterioscler. Thromb. Vasc. Biol. 24(2), 246-255 (2004). (Pubitemid 38197575)
16. Gengo FM, Rainka M, Robson M, et al. Prevalence of platelet on responsiveness to aspirin in patients treated for secondary stroke prophylaxis and in patients with recurrent ischemic events. J. Clin. Pharmacol. 48(3), 335-343 (2008). (Pubitemid 351257777)
17. Breet NJ, van Werkum JW, Bouman HJ, Kelder JC, Ten Berg JM, Hackeng CM: High on-aspirin platelet reactivity as measured with aggregation-based, cyclooxygenase-1 inhibition sensitive platelet function tests is associated with the occurrence of atherothrombotic events. J. Thromb. Haemost. 8(10), 2140-2148 (2010).
18. Snoep JD, Hovens MMC, Eikenboom JCJ, van der Bom JG, Huisman MV: Association of laboratory-defined aspirin resistance with a higher risk of recurrent cardiovascular events: a systematic review and meta-analysis. Arch. Intern. Med. 167(15), 1593-1599 (2007). (Pubitemid 47280339)
19. Angiolillo DJ, Fernandez-Ortiz A, Bernardo E, et al. Variability in individual responsiveness to clopidogrel: clinical implications, management, and future perspectives. J. Am. Coll. Cardiol. 49(14), 1505-1516 (2007). (Pubitemid 46517957)
20. Ferreiro JL, Angiolillo DJ: Clopidogrel response variability: current status and future directions. Thromb. Haemost. 102(1), 7-14 (2009).
21. Cattaneo M, Hayward CP, Moffat KA, Pugliano MT, Liu Y, Michelson AD: Results of a worldwide survey on the assessment of platelet function by light transmission aggregometry: a report from the platelet physiology subcommittee of the SSC of the ISTH. J. Thromb. Haemost. 7(6), 1029 (2009).
22. Lev EI, Patel RT, Maresh KJ, et al. Aspirin and clopidogrel drug response in patients undergoing percutaneous coronary intervention: the role of dual drug resistance. J. Am. Coll. Cardiol. 47(1), 27-33 (2006). (Pubitemid 43005160)
23. Gori AM, Marcucci R, Migliorini A, et al. Incidence and clinical impact of dual nonresponsiveness to aspirin and clopidogrel in patients with drug-eluting stents. J. Am. Coll. Cardiol. 52(9), 734-739 (2008).
24. Gori AM, Marcucci R, Paniccia R, et al. Thrombotic events in high risk patients are predicted by evaluating different pathways of platelet function. Thromb. Haemost. 100(6), 1136-1145 (2008).
25. Goto K, Lansky AJ, Fahy M, et al. Predictors of outcomes in medically treated patients with acute coronary syndromes after angiographic triage: an Acute Catheterization and Urgent Intervention Triage Strategy (ACUITY) substudy. Circulation 121(7), 853-862 (2010).
26. Poston R, Gu J, Manchio J, et al. Platelet function tests predict bleeding and thrombotic events after off-pump coronary bypass grafting. Eur. J. Cardiothorac. Surg. 27(4), 584-591 (2005). (Pubitemid 40409728)
27. Spiess BD, Gillies BS, Chandler W, et al. Changes in transfusion therapy and reexploration rate after institution of a blood management program in cardiac surgical patients. J. Cardiothorac. Vasc. Anesth. 9(2), 168-173 (1995).
28. Kwak YL, Kim JC, Choi YS, Yoo KJ, Song Y, Shim JK: Clopidogrel responsiveness regardless of the discontinuation date predicts increased blood loss and transfusion requirement after off-pump coronary artery bypass graft surgery. J. Am. Coll. Cardiol. 56(24), 1994-2002 (2010).
29. Mahla E: TARGET CABG (time based strategy to reduce clopidogrel associated bleeding during CABG) study. Late breaking clinical trial. Presented at: American Heart Association 2010. Chicago, IL, USA, 13-17 November 2010.
30. Subherwal S, Bach RG, Chen AY, et al. Baseline risk of major bleeding in non-ST-segment-elevation myocardial infarction: the CRUSADE (Can Rapid risk stratification of Unstable angina patients Suppress Adverse outcomes with Early implementation of the ACC/AHA Guidelines) bleeding score. Circulation 119(14), 1873-1882 (2009).
31. Sibbing D, Steinhubl SR, Schulz S, Schömig A, Kastrati A: Platelet aggregation and its association with stent thrombosis and bleeding in clopidogrel-treated patients: initial evidence of a therapeutic window. J. Am. Coll. Cardiol. 56(4), 317-318 (2010).
32. Campo G, Parrinello G, Ferraresi P, et al. Prospective evaluation of on-clopidogrel platelet reactivity over time in patients treated with percutaleous coronary intervention. Relationship with gene polymorphisms and clinical outcomes. J. Am. Coll. Cardiol. (2011) (In Press).
33. Michelson AD, Furman MI, Goldschmidt-Clermont P, et al. Platelet GP IIIa Pl(A) polymorphisms display different sensitivities to agonists. Circulation 101(9), 1013-1018 (2000). (Pubitemid 30131704)
34. Lim E, Carballo S, Cornelissen J, et al. Dose-related efficacy of aspirin after coronary surgery in patients with Pl A2 polymorphism. Ann. Thorac. Surg. 83(1), 134-139 (2007).
35. Undas A, Brummel K, Musial J, Mann K, Szczeklik A: Pl(A2) polymorphism of b(3) integrins is associated with enhanced thrombin generation and impaired antithrombotic action of aspirin at the site of microvascular injury. Circulation 104(22), 2666-2672 (2001). (Pubitemid 33108131)
36. Cooke GE, Bray PF, Hamlington JD, Pham DM, Goldschmidt-Clermont PJ: PlA2 polymorphism and efficacy of aspirin. Lancet 351(9111), 1253 (1998).
37. Guo Q, Kulmacz RJ: Distinct influences of carboxyl terminal segment structure on function in the two isoforms of prostaglandin H synthase. Arch. Biochem. Biophys. 384(2), 269-279 (2000). (Pubitemid 32012801)
38. Halushka MK, Walker LP, Halushka PV: Genetic variation in cyclooxygenase 1, effects on response to aspirin. Clin. Pharmacol. Ther. 73(1), 122-130 (2003). (Pubitemid 36158493)
39. Gonzalez-Conejero R, Rivera J, Corral J, et al. Biological assessment of aspirin efficacy on healthy individuals: heterogeneous response or aspirin failure? Stroke 36(2), 276-280 (2005). (Pubitemid 40170808)
40. Shiotani A, Sakakibara T, Nomura M, et al. Aspirin-induced peptic ulcer and genetic polymorphisms. J. Gastroenterol. Hepatol. 25(Suppl. 1), S31-S34 (2010).
41. Bigler J, Whitton J, Lampe JW, et al. CYP2C9 and UGT1A6 genotypes modulate the protective effect of aspirin on colon adenoma risk. Cancer Res. 61(9), 3566-3569 (2001). (Pubitemid 32694961)
42. Pilotto A, Seripa D, Franceschi M, et al. Genetic susceptibility to nonsteroidal anti-inflammatory drug-related gastroduodenal bleeding: role of cytochrome P450 2C9 polymorphisms. Gastroenterology 133(2), 465-471 (2007). (Pubitemid 47193129)
43. Undas A, Sydor WJ, Brummel K, Musial J, Mann KG, Szczeklik A: Aspirin alters the cardioprotective effects of the factor XIII Val34Leu polymorphism. Circulation 107(1), 17-20 (2003). (Pubitemid 36070925)
44. Taubert D, Kastrati A, Harlfinger S, et al. Pharmacokinetics of clopidogrel after administration of a high loading dose. Thromb. Haemost. 92(2), 311-316 (2004). (Pubitemid 39172312)
45. Mega JL, Close SL, Wiviott SD, et al. Genetic variants in ABCB1 and CYP2C19 and cardiovascular outcomes after treatment with clopidogrel and prasugrel in the TRITON-TIMI 38 trial: a pharmacogenetic analysis. Lancet 376(9749), 1312-1319 (2010).
46. Wallentin L, James S, Storey RF, et al. PLATO investigators. Effect of CYP2C19 and ABCB1 single nucleotide polymorphisms on outcomes of treatment with ticagrelor versus clopidogrel for acute coronary syndromes: a genetic substudy of the PLATO trial. Lancet 376(9749), 1320-1328 (2010).
47. Farid NA, Kurihara A, Wrighton SA: Metabolism and disposition of the thienopyridine antiplatelet drugs ticlopidine, clopidogrel, and prasugrel in humans. J. Clin. Pharmacol. 50(2), 126-142 (2010).
48. Mega JL, Close SL, Wiviott SD, et al. Cytochrome P450 genetic polymorphisms and the response to prasugrel: relationship to pharmacokinetic, pharmacodynamic, and clinical outcomes. Circulation 119(19), 2553-2560 (2009).
49. Mega JL, Simon T, Collet JP, et al. Reduced-function CYP2C19 genotype and risk of adverse clinical outcomes among patients treated with clopidogrel predominantly for PCI: a meta-analysis. JAMA 304(16), 1821-1830 (2010).
50. Sibbing D, Koch W, Gebhard D, et al. Cytochrome 2C19 17 allelic variant, platelet aggregation, bleeding events, and stent thrombosis in clopidogrel-treated patients with coronary stent placement. Circulation 121(4), 512-518 (2010).
51. Paré G, Mehta SR, Yusuf S, et al. Effects of CYP2C19 genotype on outcomes of clopidogrel treatment. N. Engl. J. Med. 363(18), 1704-1714 (2010).
52. Bouman HJ, Schömig E, van Werkum JW, et al. Paraoxonase-1 is a major determinant of clopidogrel efficacy. Nat. Med. 17(1), 110-116 (2011).
53. Hochholzer W, Trenk D, Fromm MF, et al. Impact of cytochrome P450 2C19 loss-of-function polymorphism and of major demographic characteristics on residual platelet function after loading and maintenance treatment with clopidogrel in patients undergoing elective coronary stent placement. J. Am. Coll. Cardiol. 55(22), 2427-2434 (2010).
54. Shuldiner AR, OConnell JR, Bliden KP, et al. Association of cytochrome P450 2C19 genotype with the antiplatelet effect and clinical efficacy of clopidogrel therapy. JAMA 302(8), 849-857 (2009).
55. Guthikonda S, Alviar CL, Vaduganathan M, et al. Role of reticulated platelets and platelet size heterogeneity on platelet activity after dual antiplatelet therapy with aspirin and clopidogrel in patients with stable coronary artery disease. J. Am. Coll. Cardiol. 52(9), 743-749 (2008).
56. Cesari F, Marcucci R, Caporale R, et al. Relationship between high platelet turnover and platelet function in high-risk patients with coronary artery disease on dual antiplatelet therapy. Thromb. Haemost. 99(5), 930-935 (2008). (Pubitemid 351705311)
57. Angiolillo DJ, Bernardo E, Ramirez C, et al. Insulin therapy is associated with platelet dysfunction in patients with Type 2 diabetes mellitus on dual oral antiplatelet treatment. J. Am. Coll. Cardiol. 48(2), 298-304 (2006). (Pubitemid 44026661)
58. Ueno M, Ferreiro JL, Tomasello SD, et al. Functional profile of the platelet P2Y12 receptor signaling pathway in patients with Type 2 diabetes mellitus and coronary artery disease. Thromb. Haemost. 105(4) (2011).
59. Angiolillo DJ, Fernandez-Ortiz A, Bernardo E, et al. Platelet function profiles in patients with Type 2 diabetes and coronary artery disease on combined aspirin and clopidogrel treatment. Diabetes 54(8), 2430-2435 (2005). (Pubitemid 41134272)
60. Ferreira IA, Mocking AI, Feijge MA, et al. Platelet inhibition by insulin is absent in Type 2 diabetes mellitus. Arterioscler. Thromb. Vasc. Biol. 26(2), 417-422 (2006). (Pubitemid 43732209)
61. Ferreira IA, Eybrechts KL, Mocking AI, et al. IRS-1 mediates inhibition of Ca2+ mobilization by insulin via the inhibitory G-protein Gi. J. Biol. Chem. 279(5), 3254-3264 (2004). (Pubitemid 38140559)
62. Angiolillo DJ, Capodanno D, Goto S: Platelet thrombin receptor antagonism and atherothrombosis. Eur. Heart J. 31(1), 17-28 (2010).
63. Anfossi G, Russo I, Trovati M: Platelet dysfunction in central obesity. Nutr. Metab. Cardiovasc. Dis. 19(6), 440-449 (2009).
64. Freedman JE: Oxidative stress and platelets. Arterioscler. Thromb. Vasc. Biol. 28(3), s11-s16 (2008).
65. Angiolillo DJ, Ferreiro JL: Platelet adenosine diphosphate P2Y12 receptor antagonism: benefits and limitations of current treatment strategies and future directions. Rev. Esp. Cardiol. 63(1), 60-76 (2010).
66. Collet JP, Montalescot G, Blanchet B, et al. Impact of prior use or recent withdrawal of oral antiplatelet agents on acute coronary syndromes. Circulation 110(16), 2361-2367 (2004). (Pubitemid 39407340)
67. Ho PM, Peterson ED, Wang L, et al. Incidence of death and acute myocardial infarction associated with stopping clopidogrel after acute coronary syndrome. JAMA 299(5), 532-539 (2008). (Pubitemid 351222546)
68. Bates ER, Wei L, Angiolillo DJ: Clopidogrel- drug interactions. J. Am. Coll. Cardiol. 57(11), 1251-1263 (2011).
69. Catella-Lawson F, Reilly MP, Kapoor SC, et al. Cyclooxygenase inhibitors and the antiplatelet effects of aspirin. N. Engl. J. Med. 345(25), 1809-1817 (2001).
70. MacDonald TM, Wei L: Effect of ibuprofen on cardioprotective effect of aspirin. Lancet 361(9357), 573-574 (2003). (Pubitemid 36207477)
71. Kurth T, Glynn RJ, Walker AM, et al. Inhibition of clinical benefits of aspirin on first myocardial infarction by nonsteroidal antiinflammatory drugs. Circulation 108(10), 1191-1195 (2003). (Pubitemid 37099986)
72. Kimmel SE, Berlin JA, Reilly M, et al. The effects of nonselective non-aspirin non-steroidal anti-inflammatory medications on the risk of nonfatal myocardial infarction and their interaction with aspirin. J. Am. Coll. Cardiol. 43(6), 985-990 (2004). (Pubitemid 38352976)
73. Angiolillo DJ, Gibson CM, Cheng S, et al. Differential effects of omeprazole and pantoprazole on the pharmacodynamics and pharmacokinetics of clopidogrel in healthy subjects: randomized, placebo-controlled, crossover comparison studies. Clin. Pharmacol. Ther. 89(1), 65-74 (2011).
74. Abraham NS, Hlatky MA, Antman EM, et al. ACCF/ACG/AHA 2008 expert consensus document on reducing the gastrointestinal risks of antiplatelet therapy and NSAID use: a report of the American College of Cardiology Foundation Task Force on Expert Consensus Documents. Circulation 122(24), 2619-2633 (2010).
75. Bhatt DL, Cryer BL, Contant CF, et al. COGENT Investigators. Clopidogrel with or without omeprazole in coronary artery disease. N. Engl. J. Med. 363(20), 1909-1917 (2010).
76. Angiolillo DJ, Suryadevara S, Capranzano P, et al. Antiplatelet drug response variability and the role of platelet function testing: a practical guide for interventional cardiologists. Catheter Cardiovasc. Interv. 73(1), 1-14 (2009).
77. Smith SC Jr, Allen J, Blair SN, et al. AHA/ACC National Heart, Lung, and Blood Institute. AHA/ACC guidelines for secondary prevention for patients with coronary and other atherosclerotic vascular disease: 2006 update: endorsed by the National Heart, Lung, and Blood Institute. Circulation 113(19), 2363-2372 (2006). (Pubitemid 43947981)
78. Antithrombotic Trialists Collaboration: Collaborative meta-analysis of randomized trials of antiplatelet therapy for prevention of death, myocardial infarction, and stroke in high risk patients. Br. Med. J. 324(7329), 71-86 (2002).
79. Mehta SR, Bassand JP, Chrolavicius S et al.; CURRENT-OASIS 7 Investigators: Dose comparisons of clopidogrel and aspirin in acute coronary syndromes. N. Engl. J. Med. 363(10), 930-942 (2010).
80. Gurbel PA, Bliden KP, DiChiara J, et al. Evaluation of dose-related effects of aspirin on platelet function: results from the Aspirin- Induced Platelet Effect (ASPECT) study. Circulation 115(25), 3156-3164 (2007). (Pubitemid 47012230)
81. von Beckerath N, Taubert D, Pogatsa-Murray G, et al. Absorption, metabolization, and antiplatelet effects of 300-, 600-, and 900-mg loading doses of clopidogrel: results of the ISAR-CHOICE (Intracoronary Stenting and Antithrombotic Regimen: Choose Between 3 High Oral Doses for Immediate Clopidogrel Effect) trial. Circulation 112(19), 2946-2950 (2005). (Pubitemid 41612296)
82. Angiolillo DJ, Fernández-Ortiz A, Bernardo E, et al. High clopidogrel loading dose during coronary stenting: effects on drug response and interindividual variability. Eur. Heart J. 25(1), 1903-1910 (2004). (Pubitemid 39452607)
83. Gurbel PA, Bliden KP, Hayes KM, et al. The relation of dosing to clopidogrel responsiveness and the incidence of high post-treatment platelet aggregation in patients undergoing coronary stenting. J. Am. Coll. Cardiol. 45(9), 1392-1396 (2005). (Pubitemid 40615608)
84. Montalescot G, Sideris G, Meuleman C, et al. ALBION trial investigators. A randomized comparison of high clopidogrel loading doses in patients with non-ST segment elevation acute coronary syndromes: the ALBION (Assessment of the Best Loading Dose of Clopidogrel to Blunt Platelet Activation, Inflammation and Ongoing Necrosis) trial. J. Am. Coll. Cardiol. 48(5), 931-938 (2006). (Pubitemid 44292463)
85. Patti G, Colonna G, Pasceri V, Pepe LL, Montinaro A, Di Sciascio G: Randomized trial of high loading dose of clopidogrel for reduction of periprocedural myocardial infarction in patients undergoing coronary intervention: results from the ARMYDA-2 (Antiplatelet therapy for Reduction of MYocardial Damage during Angioplasty) study. Circulation 111(16), 2099-2106 (2005). (Pubitemid 40577905)
86. Cuisset T, Frere C, Quilici J, et al. Benefit of a 600-mg loading dose of clopidogrel on platelet reactivity and clinical outcomes in patients with non-ST-segment elevation acute coronary syndrome undergoing coronary stenting. J. Am. Coll. Cardiol. 48(7), 1339-1345 (2006). (Pubitemid 44436814)
87. Lotrionte M, Biondi-Zoccai GG, Agostoni P, et al. Meta-analysis appraising high clopidogrel loading in patients undergoing percutaneous coronary intervention. Am. J. Cardiol. 100(8), 1199-1206 (2007).
88. Angiolillo DJ, Bernardo E, Palazuelos J, et al. Functional impact of high clopidogrel maintenance dosing in patients undergoing elective percutaneous coronary interventions. Results of a randomized study. Thromb. Haemost. 99(1), 161-168 (2008).
89. Angiolillo DJ, Shoemaker SB, Desai B, et al. Randomized comparison of a high clopidogrel maintenance dose in patients with diabetes mellitus and coronary artery disease: results of the Optimizing Antipla telet Therapy in Diabetes Mellitus (OPTIMUS) study. Circulation 115(6), 708-716 (2007). (Pubitemid 46294761)
90. von Beckerath N, Kastrati A, Wieczorek A, et al. A double-blind, randomized study on platelet aggregation in patients treated with a daily dose of 150 or 75 mg of clopidogrel for 30 days. Eur. Heart J. 28(15), 1814-1819 (2007). (Pubitemid 47236637)
91. Mehta SR, Tanguay JF, Eikelboom JW, et al. CURRENT-OASIS 7 trial investigators. Double-dose versus standard-dose clopidogrel and high-dose versus low-dose aspirin in individuals undergoing percutaneous coronary intervention for acute coronary syndromes (CURRENT-OASIS 7), a randomised factorial trial. Lancet 376(9748), 1233-1243 (2010).
92. Bonello L, Camoin-Jau L, Arques S, et al. Adjusted clopidogrel loading doses according to vasodilator-stimulated phosphoprotein phosphorylation index decrease rate of major adverse cardiovascular events in patients with clopidogrel resistance: a multicenter randomized prospective study. J. Am. Coll. Cardiol. 51(14), 1404-1411 (2008). (Pubitemid 351447314)
93. Bonello L, Lemesle G, De Labriolle A, et al. Impact of a 600-mg loading dose of clopidogrel on 30-day outcome in unselected patients undergoing percutaneous coronary intervention. Am. J. Cardiol. 102(10), 1318-1322 (2008).
94. Price MJ, Berger PB, Teirstein PS, et al. GRAVITAS Investigators. Standard- vs high-dose clopidogrel based on platelet functiontesting after percutaneous coronary intervention: the GRAVITAS randomized trial. JAMA 305(11), 1097-1105 (2011).
95. Collet JP, Hulot JS: Pena A, et al. High Doses of Clopidogrel to Overcome Genetic Resistance The Randomized Crossover CLOVIS-2 (Clopidogrel and Response Variability Investigation Study 2). JACC Cardiovasc. Interv. 4(4), 392-402 (2011).
96. Jeong YH, Kim IS, Park Y, et al. Carriage of cytochrome 2C19 polymorphism is associated with risk of high post-treatment platelet reactivity on high maintenance-dose clopidogrel of 150 mg/day: results of the ACCEL-DOUBLE (Accelerated Platelet Inhibition by a Double Dose of Clopidogrel According to Gene Polymorphism) study. JACC Cardiovasc. Interv. 3(7), 731-741 (2010).
97. Barker CM, Murray SS, Teirstein PS, Kandzari DE, Topol EJ, Price MJ: Pilot study of the antiplatelet effect of increased clopidogrel maintenance dosing and its relationship to CYP2C19 genotype in patients with high on-treatment reactivity. JACC Cardiovasc. Interv. 3(10), 1001-1007 (2010).
98. Gurbel PA, Bliden KP, Zaman KA, et al. Clopidogrel loading with eptifibatide to arrest the reactivity of platelets: results of the Clopidogrel Loading With Eptifibatide to Arrest the Reactivity of Platelets (CLEAR PLATELETS) study. Circulation 111(9), 1153-1159 (2005). (Pubitemid 40365477)
99. Cuisset T, Frere C, Quilici J, et al. Glycoprotein IIb/IIIa inhibitors improve outcome after coronary stenting in clopidogrel nonresponders. JACC Cardiovasc. Interv. 1(6), 649-653 (2008).
100. Valgimigli M, Campo G, de Cesare N et al.; Tailoring Treatment with Tirofiban in Patients Showing Resistance to Aspirin and/or Resistance to Clopidogrel (3T/2R) investigators: Intensifying platelet inhibition with tirofiban in poor responders to aspirin, clopidogrel, or both agents undergoing elective coronary intervention: results from the double-blind, prospective, randomized Tailoring Treatment with Tirofiban in Patients Showing Resistance to aspirin and/or Resistance to Clopidogrel study. Circulation 119(25), 3215-3222 (2009).
101. Campo G, Fileti L, de Cesare N, et al. 3T/2R Investigators. Long-term clinical outcome based on aspirin and clopidogrel responsiveness status after elective percutaneous coronary intervention: a 3T/2R (Tailoring Treatment with Tirofiban in Patients Showing Resistance to Aspirin and/or Resistance to Clopidogrel) trial substudy. J. Am. Coll. Cardiol. 56(18), 1447-1455 (2010).
102. Jeong YH, Hwang JY, Kim IS, et al. Adding cilostazol to dual antiplatelet therapy achieves greater platelet inhibition than high maintenance dose clopidogrel in patients with acute myocardial infarction: results of the Adjunctive Cilostazol Versus High Maintenance Dose Clopidogrel in Patients with AMI (ACCEL-AMI) study. Circ. Cardiovasc. Interv. 3(1), 17-26 (2010).
103. Jeong YH, Lee SW, Choi BR, et al. Randomized comparison of adjunctive cilostazol versus high maintenance dose clopidogrel in patients with high post-treatment platelet reactivity: results of the ACCEL-RESISTANCE (Adjunctive Cilostazol Versus High Maintenance Dose Clopidogrel in Patients With Clopidogrel Resistance) randomized study. J. Am. Coll. Cardiol. 53(13), 1101-1109 (2009).
104. Hwang SJ, Jeong YH, Kim IS, et al. Cytochrome 2C19 polymorphism and response to adjunctive cilostazol versus high maintenance-dose clopidogrel in patients undergoing percutaneous coronary intervention. Circ. Cardiovasc. Interv. 3(5), 450-459 (2010).
105. Lee SW, Park SW, Yun SC, et al. Triple antiplatelet therapy reduces ischemic events after drug-eluting stent implantation: Drug-Eluting stenting followed by Cilostazol treatment REduces Adverse Serious cardiac Events (DECREASE registry). Am. Heart J. 159(2), 284-291.e1 (2010).
106. Lee SW, Park SW, Hong MK, et al. Triple versus dual antiplatelet therapy after coronary stenting: impact on stent thrombosis. J. Am. Coll. Cardiol. 46(10), 1833-1837 (2005).
107. Angiolillo DJ, Capranzano P, Goto S, et al. A randomized study assessing the impact of cilostazol on platelet function profiles in patients with diabetes mellitus and coronary artery disease on dual antiplatelet therapy: results of the OPTIMUS-2 study. Eur. Heart J. 29, 2202-2211 (2008).
108. Angiolillo DJ, Ueno M, Goto S: Basic principles of platelet biology and clinical implications. Circ. J. 74(4), 597-607 (2010).
109. Neri Serneri GG, Coccheri S, Marubini E, Violi F; Drug Evaluation in Atherosclerotic Vascular Disease in Diabetics (DAVID) Study Group: Picotamide, a combined inhibitor of thromboxane A2 synthase and receptor, reduces 2-year mortality in diabetics with peripheral arterial disease: the DAVID study. Eur. Heart J. 25(20), 1845-1852 (2004). (Pubitemid 39330236)
110. Capodanno D, Dharmashankar K, Angiolillo DJ: Mechanism of action and clinical development of ticagrelor, a novel platelet ADP P2Y12 receptor antagonist. Expert Rev. Cardiovasc. Ther. 8(2), 151-158 (2010).
111. Tomasello SD, Tello-Montoliu A, Angiolillo DJ: Prasugrel for the treatment of coronary thrombosis: a review of pharmacological properties, indications for use and future development. Expert Opin. Investig. Drugs 20(1), 119-133 (2011).
112. Wiviott SD, Braunwald E, McCabe CH, et al. TRITON-TIMI 38 Investigators. Prasugrel versus clopidogrel in patients with acute coronary syndromes. N. Engl. J. Med. 357(20), 2001-2015 (2007). (Pubitemid 350106708)
113. Wallentin L, Becker RC, Budaj A et al.; PLATO Investigators: Ticagrelor versus clopidogrel in patients with acute coronary syndromes. N. Engl. J. Med. 361(11), 1045-1057 (2009).
114. Alexopoulos D, Dimitropoulos G, Davlouros P, et al. Prasugrel Overcomes High On-Clopidogrel Platelet Reactivity Post- Stenting More Effectively Than High-Dose (150-mg) Clopidogrel The Importance of CYP2C192 Genotyping. JACC Cardiovasc. Interv. 4(4), 403-410 (2011).
115. Ferreiro JL, Ueno M, Angiolillo DJ: Cangrelor: a review on its mechanism of action and clinical development. Expert Rev. Cardiovasc. Ther. 7(10), 1195-1201 (2009).
116. Ueno M, Rao SV, Angiolillo DJ: Elinogrel: pharmacological principles preclinical and early phase clinical testing. Future Cardiol. 6(4), 445-453 (2010).
117. Grotemeyer KH, Scharafinski HW, Husstedt IW: Two-year follow-up of aspirin responder and aspirin non responder: a pilot-study including 189 post-stroke patients. Thromb. Res. 71(5), 397-403 (1993).
118. Buchanan MR, Schwartz L, Bourassa M, Brister SJ, Peniston CM: Results of the BRAT study: a pilot study investigating the possible significance of ASA nonresponsiveness on the benefits and risks of ASA on thrombosis in patients undergoing coronary artery bypass surgery. Can. J. Cardiol. 16 (11), 1385-1390 (2000). (Pubitemid 32094223)
119. Andersen K, Hurlen M, Arnesen H, Seljeflot I: Aspirin non-responsiveness as measured by PFA-100 in patients with coronary artery disease. Thromb. Res. 108 (1), 37-42 (2002). (Pubitemid 36197660)
120. Gum PA, Kottke-Marchant K, Welsh PA, White J, Topol EJ: A prospective, blinded determination of the natural history of aspirin resistance among stable patients with cardiovascular disease. J. Am. Coll. Cardiol. 41(6), 961-965 (2003). (Pubitemid 36315537)
121. Cotter G, Shemesh E, Zehavi M, et al. Lack of aspirin effect: aspirin resistance or resistance to taking aspirin? Am. Heart J. 147(2), 293-300 (2004). (Pubitemid 38176831)
122. Pamukcu B, Oflaz H, Oncul A, et al. The role of aspirin resistance on outcome in patients with acute coronary syndrome and the effect of clopidogrel therapy in the prevention of major cardiovascular events. J. Thromb. Thrombolysis 22(2), 103-110 (2006). (Pubitemid 44473559)
123. Stejskal D, Václavík J, Lacnák B, Prosková J: Aspirin resistance measured by cationic propyl gallate platelet aggregometry and recurrent cardiovascular events during 4 years of follow-up. Eur. J. Intern. Med. 17(5), 349-354 (2006). (Pubitemid 44080547)
124. Mueller MR, Salat A, Stangle P, et al. Variable platelet response to low-dose ASA and the risk of limb deterioration in patients submitted to peripheral arterial angioplasty. Thromb. Haemost. 78(3), 1003-1007 (1997). (Pubitemid 27417291)
125. Ziegler S, Maca T, Alt E, Speiser W, Schneider B, Minar E: Monitoring of antiplatelet therapy with the PFA-100 in peripheral angioplasty patients. Platelets 13(8), 493-497 (2002). (Pubitemid 35373664)
126. Poston RS, Gu J, Brown JM, et al. Endothelial injury and acquired aspirin resistance as promoters of regional thrombin formation and early vein graft failure after coronary artery bypass grafting. J. Thorac. Cardiovasc. Surg. 131(1), 122-130 (2006). (Pubitemid 43049792)
127. Chen WH, Lee PY, Ng W, Tse HF, Lau CP: Aspirin resistance is associated with a high incidence of myonecrosis after non-urgent percutaneous coronary intervention despite clopidogrel pretreatment. J. Am. Coll. Cardiol. 43(6), 1122-1126 (2004). (Pubitemid 38353000)
128. Barragan P, Bouvier JL, Roquebert PO, et al. Resistance to thienopyridines: clinical detection of coronary stent thrombosis by monitoring of vasodilator stimulated phosphoprotein phosphorylation. Catheter Cardiovasc. Interv. 59 (3),295-302 (2003). (Pubitemid 36792384)
129. Gurbel PA, Bliden KP, Guyer K, et al. Platelet reactivity in patients and recurrent events post-stenting: results of the PREPARE POSTSTENTING Study. J. Am. Coll. Cardiol. 46 (10), 1820-1826 (2005). (Pubitemid 41579802)
130. Matetzky S, Shenkman B, Guetta V, et al. Clopidogrel resistance is associated with increased risk of recurrent atherothrombotic events in patients with acute myocardial infarction. Circulation 109 (25), 171-175 (2004).
131. Gurbel PA, Bliden KP, Saucedo JF, et al. Bivalirudin and clopidogrel with and without eptifibatide for elective stenting: effects on platelet function, thrombelastographic indices and their relation to periprocedural infarction: results of the CLEAR PLATELETS-2 study. J. Am. Coll. Cardiol. 53(8),648-657 (2009).
132. Bliden KP, DiChiara J, Tantry US, Bassi AK, Chaganti SK, Gurbel PA: Increased risk in patients with high platelet aggregation receiving chronic clopidogrel therapy undergoing percutaneous coronary intervention: Is the current antiplatelet therapy adequate? J. Am. Coll. Cardiol. 49 (6), 657-666 (2007). (Pubitemid 46205039)
133. Blindt R, Stellbrink K, de Taeye A, et al. The significance of vasodilator-stimulated phosphoprotein for risk stratification of stent thrombosis. Thromb. Haemost. 98(6), 1329-1334 (2007). (Pubitemid 350239106)
134. Cuisset T, Frere C, Quilici J, et al. High post-treatment platelet reactivity is associated with a high incidence of myonecrosis after stenting for non-ST elevation acute coronary syndromes. Thromb. Haemost. 97(2), 282-287 (2007). (Pubitemid 46592149)
135. Frere C, Cuisset T, Quilici J, et al. ADP-induced platelet aggregation and platelet reactivity index VASP are good predictive markers for clinical outcomes in non-ST elevation acute coronary syndrome. Thromb. Haemost. 98(4), 838-843 (2007). (Pubitemid 47555077)
136. Geisler T, Langer H, Wydymus M, et al. Low response to clopidogrel is associated with cardiovascular outcome after coronary stent implantation. Eur. Heart J. 27 (20), 2420-2425 (2006). (Pubitemid 44522148)
137. Geisler T, Grass D, Bigalke B, et al. The Residual Platelet Aggregation after Deployment of Intracoronary Stent (PREDICT) score. J. Thromb. Haemost. 6(1), 54-61 (2008).
138. Hochholzer W, Trenk D, Bestehorn HP, et al. Impact of the degree of peri-interventional platelet inhibition after loading with clopidogrel on early clinical outcome of elective coronary stent placement. J. Am. Coll. Cardiol. 48(9), 1742-1750 (2006). (Pubitemid 44648629)
139. Price MJ, Endemann S, Gollapudi RR, et al. Prognostic significance of post-clopidogrel platelet reactivity assessed by a point-of-care assay on thrombotic events after drug-eluting stent implantation. Eur. Heart J. 29 (8), 992-1000 (2008). (Pubitemid 351844676)
140. Gurbel PA, Antonino MJ, Bliden KP, et al. Platelet reactivity to adenosine diphosphate and long-term ischemic event occurrence following percutaneous coronary intervention: a potential antiplatelet therapeutic target. Platelets 19(8), 595-604 (2008).
141. Gurbel PA, Bliden KP, Samara W, et al. Clopidogrel effect on platelet reactivity in patients with stent thrombosis: results of the CREST Study. J. Am. Coll. Cardiol. 46 (10), 1827-1832 (2005). (Pubitemid 41579803)
142. Buonamici P, Marcucci R, Miglironi A, et al. Impact of platelet reactivity after clopidogrel administration on drug-eluting stent thrombosis. J. Am. Coll. Cardiol. 49(24), 2312-2317 (2007). (Pubitemid 46891710)
143. Bonello L, Paganelli F, Arpin-Bornet M, et al. Vasodilator stimulated phosphoprotein phosphorylation analysis prior to percutaneous coronary intervention for exclusion of postprocedural major adverse cardiovascular events. J. Thromb. Haemost. 5(8), 1630-1636 (2007). (Pubitemid 47091403)
144. Cuisset T, Hamilos M, Sarma J, et al. Relation of low response to clopidogrel assessed with point-of-care assay to periprocedural myonecrosis in patients undergoing elective coronary stenting for stable angina pectoris. Am. J. Cardiol. 101(12), 1700-1703 (2008).
145. Migliorini A, Valenti R, Marcucci R, et al. High residual platelet reactivity after clopidogrel loading and long-term clinical outcome after drug-eluting stenting for unprotected left main coronary disease. Circulation 120(22), 2214-2221 (2009).
146. Marcucci R, Gori AM, Paniccia R, et al. Cardiovascular death and nonfatal myocardial infarction in acute coronary syndrome patients receiving coronary stenting are predicted by residual platelet reactivity to ADP detected by a point-of-care assay: a 12-month follow-up. Circulation 119(2), 237-342 (2009).
147. Bonello L, Camoin-Jau L, Armero S, et al. Tailored clopidogrel loading dose according to platelet reactivity monitoring to prevent acute and subacute stent thrombosis. Am. J. Cardiol. 103(1), 5-10 (2009).
148. Patti G, Nusca A, Mangiacapra F, Gatto L, DAmbrosio A, Di Sciascio G: Point-of-care measurement of clopidogrel responsiveness predicts clinical outcome in patients undergoing percutaneous coronary intervention results of the ARMYDA-PRO (Antiplatelet therapy for Reduction of MYocardial Damage during Angioplasty- Platelet Reactivity Predicts Outcome) study. J. Am. Coll. Cardiol. 52(14), 1128-33 (2008).
149. Sibbing D, Braun S, Morath T, et al. Platelet reactivity after clopidogrel treatment assessed with point-of-care analysis and early drug-eluting stent thrombosis. J. Am. Coll. Cardiol. 53(10), 849-856 (2009).
150. Cuisset T, Frere C, Quilici J, et al. Predictive values of post-treatment adenosine diphosphate-induced aggregation and vasodilator- stimulatedphosphoprotein index for stent thrombosis after acute coronary syndrome in clopidogrel-treated patients. Am. J. Cardiol. 104(8), 1078-1082 (2009).
151. Breet NJ, Van Werkum JW, Bouman HJ, et al. Comparison of platelet function tests in predicting clinical outcome in patients undergoing coronary stent implantation. JAMA 303(8), 754-762 (2010).
152. Chen L, Bracey AW, Radovancevic R, et al. Clopidogrel and bleeding in patients undergoing elective coronary artery bypass grafting. J. Thorac. Cardiovasc. Surg. 128(3), 425-431 (2004). (Pubitemid 39194700)
153. Rahe-Meyer N, Winterhalter M, Boden A, et al. Platelet concentrates transfusion in cardiac surgery and platelet function assessment by multiple electrode aggregometry. Acta Anaesthesiol. Scand. 53(2), 168-175 (2009).
154. Cuisset T, Cayla G, Frere C, et al. Predictive value of post-treatment platelet reactivity for occurrence of post-discharge bleeding after non-ST elevation acute coronary syndrome. Shifting from antiplatelet resistance to bleeding risk assessment? EuroIntervention 5(3), 325-329 (2009).
155. Sibbing D, Schulz S, Braun S, et al. Antiplatelet effects of clopidogrel and bleeding in patients undergoing coronary stent placement. J. Thromb. Haemost. 8(2), 250-256 (2010).
156. Serebruany V, Rao SV, Silva MA, et al. Correlation of inhibition of platelet aggregation after clopidogrel with post discharge bleeding events: assessment by different bleeding classifications. Eur. Heart J. 31(2), 227-235 (2010).
157. Michelson AD, Frelinger AL, Braunwald E, et al. for the TRITON-TIMI 38 Investigators. Pharmacodynamic assessment of platelet inhibition by prasugrel versus clopidogrel in the TRITON-TIMI 38 Trial. Eur. Heart J. 30(14), 1753-1763 (2009).
158. Double Randomization of a Monitoring Adjusted Antiplatelet Treatment Versus a Common Antiplatelet Treatment for DES Implantation, and Interruption Versus Continuation of Double Antiplatelet Therapy (ARCTIC) http:// clinicaltrials.gov/ct2/show/NCT00827411
159. Dual Antiplatelet Therapy Tailored on the Extent of Platelet Inhibition (DANTE) http://clinicaltrials.gov/ct2/show/NCT00774475
160. Tailoring Of Platelet Inhibition to Avoid Stent Thrombosis (TOPAS-1) http://clinicaltrials.gov/ct2/show/NCT00914368
161. Testing Platelet Reactivity In Patients Undergoing Elective Stent Placement on Clopidogrel to Guide Alternative Therapy With Prasugrel (TRIGGER-PCI) http://clinicaltrials.gov/ct2/show/NCT00910299